Table.

Risk of herpes zoster: Results of adjusted regression analyses with and without inverse probability weights

Multivariate Analysis
without IPW
Multivariate Analysis
with IPW
Adjusted HR (95% CI)P ValueAdjusted HR (95% CI)P Value
Female sex1.42 (1.12-1.82)0.00421.21 (0.96-1.53)0.1095
Age per 10 years1.23 (1.13-1.33)<.00011.31 (1.2-1.43)<.0001
Glucocorticoids, 5-10 vs 0 mg/d1.16 (0.95-1.41)0.15771.23 (1-1.52)0.0501
Glucocorticoids, >10 vs 0 mg/d1.58 (1.02-2.46)0.04171.92 (1.27-2.92)0.0022
csDMARD treatmentReference Reference
Monoclonal TNFi antibodies1.55 (1.20-2.00)0.00091.63 (1.25-2.12)0.0003
Soluble TNF receptors1.32 (0.98-1.77)0.06831.34 (0.98-1.83)0.0631
T-cell co-stimulation modulator1.41 (0.97-2.05)0.07461.69 (1.17-2.45)0.0048
B-cell targeted therapies1.45 (1.07-1.97)0.01561.66 (1.19-2.3)0.0026
IL-6 inhibitors1.31 (0.97-1.77)0.07371.55 (1.15-2.09)0.0045
JAK inhibitors3.55 (2.33-5.41)<.00015.01 (3.45-7.28)<.0001